findmyKOL

Koji Sasaki, MD, PhD

Enriched profile

Adjunct Professor, Department of Leukemia, The University of Texas MD Anderson Cancer Center (concurrently Chair and Professor, Department of Laboratory Medicine, Institute of Science Tokyo, since December 1, 2025) · Institute of Science Tokyo

ORCIDNPI
Region🇺🇸 Houston, TX · South Central · United StatesSpecialtyHematology / OncologyFocusAcute Myeloid Leukemia Research+4
Active KOLfindmyKOL typefindmyKOL type: our influence ranking, shown when you reveal the full profileLatest publication2026Online presenceverified 2026Payments2021–2025NIH fundingNone on fileWhy? →

Koji Sasaki is Adjunct Professor, Department of Leukemia, The University of Texas MD Anderson Cancer Center (concurrently Chair and Professor, Department of Laboratory Medicine, Institute of Science Tokyo, since December 1, 2025) at Institute of Science Tokyo. OpenAlex indexes 1,089 publications with 15,297 citations (h-index 62); ClinicalTrials.gov lists 1 registered study with this person as an investigator.

Data verified 14 Aug 2026

Overview

Updated 27 Aug 2026

Koji Sasaki, M.D., is Adjunct Professor, Department of Leukemia, The University of Texas MD Anderson Cancer Center (concurrently Chair and Professor, Department of Laboratory Medicine, Institute of Science Tokyo, since December 1, 2025). The public record shows 1,089 publications with 15,297 citations (h-index 62), centered on Acute Myeloid Leukemia Research, Chronic Myeloid Leukemia Treatments, Acute Lymphoblastic Leukemia research. It also documents an investigator role on 1 registered clinical trials, industry payments reported by 10 companies.

  • Most recent indexed publication: 2026 · Blood advances
  • Top research focus: Acute Myeloid Leukemia Research
  • 1 registered trials on ClinicalTrials.gov
  • Open Payments reporting from 10 companies

Generated from the cited public record · current as of 27 Aug 2026. Every fact links its source below.

Indications focus

from trials led + research topics
Leukemia (AML/ALL/CML/CLL)1 trialMDS / MPN

Research focus

OpenAlex concept fingerprint
Acute Myeloid Leukemia ResearchChronic Myeloid Leukemia TreatmentsAcute Lymphoblastic Leukemia researchChronic Lymphocytic Leukemia ResearchMyeloproliferative Neoplasms: Diagnosis and Treatment

Drugs & molecules

across trials, industry payments and publications
Iclusiggeneric · PonatinibClinical trialsIndustry payments26Publications12Blincytogeneric · BlinatumomabClinical trialsIndustry payments9Publications8Scemblixgeneric · AsciminibClinical trialsIndustry payments1Publications9

Works with

trial sponsors and companies reporting payments
Otsuka Pharmaceutical Co., Ltd.Clinical trialsIndustry payments26Amgen Inc.Clinical trialsIndustry payments9Novartis Pharmaceuticals CorporationClinical trialsIndustry payments8

Scholarship

indexed output and impact (OpenAlex)
View publications ↓
1,089publications

Distinct works indexed by OpenAlex, matched via ORCID; 171 in PubMed.

15,297citations

Total citations across indexed works.

62h-index

Hirsch index (OpenAlex). i10-index 268.

Clinical & industry

trials, payments and federal funding
1clinical trials

Investigator role on registered studies.

View trials
10companies · 2021–2025

Companies reporting payments to CMS. Facts, not judgments.

View payments
0NIH grants

Federally funded research awards.

Contact

The practice address and phone this provider lists in the federal NPPES (CMS) registry.

Practice address

Telephone

Practice address and telephone from the federal NPPES registry.

Sign in to view contact details →

Clinical trials

Updated 27 Aug 2026

Listed as an investigator on 1 registered study on ClinicalTrials.gov. The most recent:

Industry payments

Updated 27 Aug 2026

10 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:

Medicare prescribing footprint (2024)

The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.

  • Cancer & immunology

    64%
    BCL-2 Inhibitor36%
    Venclexta100%
    Part D12 patients
    Isocitrate Dehydrogenase 2 Inhibitor16%
    Idhifa100%
    Part D<11 patients
  • Anti-infectives

    36%
    Herpesvirus Nucleoside Analog DNA Polymerase Inhibitor15.2%
    Valacyclovir100%
    Part D<11 patients
    Azole Antifungal12%
    Posaconazole100%
    Part D<11 patients
Where care is delivered (Part B)91.3% facility · 8.7% office

Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.

NIH funding

We didn't find any NIH-funded research awards for this person in NIH RePORTER. Why? →

Publications

Updated 27 Aug 2026

Their five most recent publications, matched to their ORCID record and linked to PubMed.

Network

Updated 27 Aug 2026

The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.

Online presence

Updated 27 Aug 2026

This person's own public accounts first, then places where others mention them. Two different things, listed separately.

Owned accounts

public accounts run by this person
  • Doximity

    doximity.com/pub/koji-sasaki-md

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com
  • LinkedIn

    linkedin.com/in/koji-sasaki-m-d-ph-d-8b6759148

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →linkedin.com
  • ResearchGate

    researchgate.net/profile/Koji-Sasaki-6

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →researchgate.net

Mentions by others

where others cite or feature them
  • LinkedIn

    LinkedIn: Koji Sasaki, M.D., Ph.D. - MD Anderson Cancer Center

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →linkedin.com
  • Google Scholar

    Google Scholar profile (Koji Sasaki / 佐々木 宏治)

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →scholar.google.com

We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.

Background & recognition

Updated 27 Aug 2026

Credentials, appointments and honors, newest first, each linked to the public source it came from.

Education

degrees and training on record

Editorial & leadership roles

journal and society appointments

Awards & honors

honors on the public record
1 more award behind the reveal.Reveal →

Secondary affiliations

appointments beyond the home institution
  • Adjunct Professor

    Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX

    2025
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →pub.orcid.org

Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.

Similar KOLs

Other experts from the same institution or the same specialty.